Literature DB >> 17085123

Characteristics of patients with familial versus sporadic prostate cancer.

Kimberly A Roehl1, Stacy Loeb, Jo Ann V Antenor, Nicol Corbin, William J Catalona.   

Abstract

PURPOSE: There are conflicting reports concerning whether prostate cancer in families with multiple affected members has different clinical and pathological features than sporadic cases. In our study we compared the clinical characteristics, pathological outcomes and the 7-year biochemical progression-free rate in patients with apparent sporadic prostate cancer, affected sibling pairs, families with multiple affected members and families meeting the Johns Hopkins criteria for hereditary prostate cancer.
MATERIALS AND METHODS: From 1983 to 2003, 3,478 men underwent radical retropubic prostatectomy by a single surgeon (WJC). Of these men 1,186 reported family history status. We compared age at surgery, prostate specific antigen at diagnosis, pathological tumor stage, Gleason score, tumor characteristics and 7-year biochemical progression-free survival rates in the groups using chi-square, 1-way ANOVA or Cox proportional hazards regression analysis.
RESULTS: The 7-year biochemical progression-free survival rates were 81% for sporadic cases, 71% for sibling pairs, 72% for hereditary cases and 81% for high density family members (p = 0.3). Of the clinical and pathological features examined only age (p <0.0001) and positive surgical margin rate (p = 0.03) were significantly different among groups.
CONCLUSIONS: In our study population clinicopathological features and progression-free survival are similar between sporadic and familial prostate cancer cases. The sibling pairs had a trend toward less favorable tumor features and progression-free survival, but the difference was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085123     DOI: 10.1016/j.juro.2006.07.159

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Influence of family history on psychosocial distress and perceived need for treatment in prostate cancer survivors.

Authors:  Andreas Dinkel; Marielouise Kornmayer; Jürgen E Gschwend; Birgitt Marten-Mittag; Peter Herschbach; Kathleen Herkommer
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

2.  Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy.

Authors:  Mary E Westerman; Boris Gershman; R Jeffrey Karnes; R Houston Thompson; Laureano Rangel; Stephen A Boorjian
Journal:  World J Urol       Date:  2015-12-09       Impact factor: 4.226

3.  Survival in non-Hodgkin's lymphoma by histology and family history.

Authors:  Jianguang Ji; Asta Försti; Jan Sundquist; Per Lenner; Kari Hemminki
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-17       Impact factor: 4.553

4.  A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).

Authors:  Marco Randazzo; Alexander Müller; Sigrid Carlsson; Daniel Eberli; Andreas Huber; Rainer Grobholz; Lukas Manka; Ashkan Mortezavi; Tullio Sulser; Franz Recker; Maciej Kwiatkowski
Journal:  BJU Int       Date:  2015-10-06       Impact factor: 5.588

5.  Application of the 2013 American Urological Association early detection of prostate cancer guideline: who will we miss?

Authors:  Gregory B Auffenberg; Joshua J Meeks
Journal:  World J Urol       Date:  2014-06-20       Impact factor: 4.226

6.  A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy.

Authors:  Omer A Raheem; Seth A Cohen; J Kellogg Parsons; Kerrin L Palazzi; Christopher J Kane
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

7.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Authors:  Elena Castro; Chee Goh; David Olmos; Ed Saunders; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Nadiya Mahmud; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Emma Sawyer; Rosemary Wilkinson; Audrey Ardern-Jones; Steve Ellis; Debra Frost; Susan Peock; D Gareth Evans; Marc Tischkowitz; Trevor Cole; Rosemarie Davidson; Diana Eccles; Carole Brewer; Fiona Douglas; Mary E Porteous; Alan Donaldson; Huw Dorkins; Louise Izatt; Jackie Cook; Shirley Hodgson; M John Kennedy; Lucy E Side; Jacqueline Eason; Alex Murray; Antonis C Antoniou; Douglas F Easton; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

8.  Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis.

Authors:  Fumihiko Urabe; Shoji Kimura; Shutaro Yamamoto; Kojiro Tashiro; Takahiro Kimura; Shin Egawa
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-15       Impact factor: 5.554

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.